Thailand Pharmaceuticals and Healthcare Report Q1 2009
Business Monitor International, February 2009, Pages: 83
Thailand Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Thailand's pharmaceuticals and healthcare industry.
In the Business Environment Ranking matrix for Q109, Thailand has significantly improved its position, now ranked ninth out of the15 regional markets surveyed in the Asia Pacific region, up from a shared 12th in the previous quarter. Thailand’s growing and ageing population represents a substantial commercial opportunity for drugmakers, although its precarious political climate and the controversial compulsory licensing scheme are deterring foreign investment and involvement in its pharmaceutical market, with a potential to lead to international sanctions.
Nevertheless, by September 2008, none of the six pharmaceutical compulsory licences sought by the Thai government had received formal certification. The situation was blamed on legal hurdles, as Thailand's Council of State is still considering processes related to the official granting and working of the licences. However, the Government Pharmaceutical Organisation (GPO) is already producing and marketing the heart drug Plavix (clopidogrel), which has not yet been approved by the compulsory licensing scheme. In addition, the GPO intends to follow up of the success of Plavix with another medicine obtained via a compulsory licence, the anticancer agent Taxotere (docetaxel), which has been imported from India and is to go on sale imminently. While the GPO also announced that it expects sales growth to decrease significantly over the next financial year (FY) owing to a challenging operating environment, its FY08 (year ending September 30 2008) sales were 14% higher year-on-year (y-o-y).
Similarly, despite Thailand's current economic and political turmoil, Bayer Schering Pharma stated that it expects the country's pharmaceutical market to continue its promising growth trajectory. This is mainly due to the government's strong commitment to providing public healthcare, but also the buoyant medical tourism sector. Moreover, the German drugmaker expects its business ‘to grow in line with the market or even over the market average'.
In other news, in October 2008, the Thai National Center for Genetic Engineering and Biotechnology (Biotec) unveiled a White Paper entitled Thailand Updated Status and Perspective on Research and Development of Modern Biotechnology and Bio-safety Regulation. The publication aims to promote the country’s readiness to embrace biotechnology applications, with a focus on genetic engineering, as Thailand continues working to attract global investors in the field. However, although the Ministry of Public Health has already streamlined clinical trial procedures, foreign companies continue to criticise weak data protection laws, which require a company that funds clinical trials to hand over its data to the government prior to receiving market approval.
Executive Summary 5
Vietnam Pharmaceutical And Healthcare Industry SWOT 6
Vietnam Political SWOT 7
Vietnam Economics SWOT 8
Vietnam Business Environment SWOT 9
Vietnam – Business Environment Rankings10
Table: Asia Pacific Pharmaceutical Business Environment Rankings For Q109 10
Limits Of Potential Returns 10
Risks To Realisation Of Returns 11
Market Summary 12
Regulatory Regime14
Pharmaceutical Advertising 14
Intellectual Property Environment 15
IP Shortcomings 15
Counterfeit Drugs 17
Other Regulatory Issues 17
Pricing And Reimbursement Regime 18
Industry Trends And Developments 20
Epidemiology 20
Healthcare Financing 23
Healthcare Insurance 24
Healthcare And Pharmaceutical Reforms 25
Foreign Partnerships 26
Domestic Pharmaceutical Sector 27
Recent Pharmaceutical Industry Developments 28
Foreign Pharmaceutical Sector 29
Traditional Medicines 30
Retail Sector 30
Table: Key Aspects Of Good Pharmacy Practice (GPP) In Developing Countries 31
Research And Development 31
Vaccine Sector 32
Biotechnology Sector 33
Industry Forecast Scenario 35
Overall Market Forecast 35
Table: Vietnam – Pharmaceutical Expenditure, 2003-2013 36
Key Growth Factors – Industry 37
Key Growth Factors – Industry 37
Table: Vietnam – Health Expenditure, 2003-2013 38
Key Growth Factors – Macroeconomic 39
Table: Vietnam – Economic Activity 41
Prescription Market Forecast 42
Table: Vietnam – Prescription Market Indicators, 2003-2013 (VNDmn unless otherwise stated) 43
OTC Market Forecast 44
Table: Vietnam – OTC Medicine Expenditure, 2003-2013 (VNDmn unless otherwise stated) 45
Patented Market Forecast 46
Patented Market Forecast 46
Table: Vietnam – Patented Product Expenditure, 2003-2013 47
Generic Market Forecasts 48
Table: Vietnam – Generics Drug Expenditure, 2003-2013 49
Export/Import Forecasts 50
Table: Vietnam – Pharmaceutical Trade Indicators, 2003-2013 (US$mn) 51
Medical Device Market Forecast 52
Table: Vietnam’s Medical Device Market (US$mn unless otherwise stated) 54
Other Healthcare Data Forecasts 55
Table: Vietnam – Other Healthcare Indicators, 2003-2012 55
Key Risks To BMI’s Forecast Scenario 56
Competitive Landscape57
Company Profiles58
Leading Multinational Manufacturers 58
Pfizer 58
GlaxoSmithKline 60
Sanofi-Aventis 62
Novartis 64
Merck & Co 65
Indigenous Manufacturer Profiles 66
Vietnam Pharmaceutical Corporation (Vinapharm) 66
Vietnam OPV Pharmaceutical Co 68
Stada Vietnam 70
Vietnam Pharmaceutical Joint Stock Company (Ampharco) 72
Vidipha Central Pharmaceutical Joint Stock Company 74
Country Snapshot: Vietnam Demographic Data75
Section 1: Population 75
Table: Demographic Indicators, 2005-2030 75
Table: Rural/Urban Breakdown, 2005-2030 76
Section 2: Education And Healthcare 76
Table: Education, 2002-2005 76
Table: Vital Statistics, 2005-2030 76
Section 3: Labour Market And Spending Power 77
Table: Employment Indicators, 1999-2004 77
Table: Consumer Expenditure, 2000-2012 (US$) 77
Forecast Modelling78
How We Generate Our Pharmaceutical Industry Forecasts 78
Pharmaceutical Business Environment Ratings Methodology 79
Ratings Overview 79
Table: Pharmaceutical Business Environment Indicators 80
Weighting 81
Table: Weighting Of Components 81
Sources 81
-Pfizer
-Sanofi-Aventis
-Novartis
-GlaxoSmithKline
-Merck & Co
-Domestic Manufacturer Profiles
-Siam Pharmaceutical
-Government Pharmaceutical Organisation (GPO)
-Biolab Co
-Thai Meiji Pharmaceutical Co
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
